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Abstract: Endogenous estrogens can be bio-activated to endogenous carcinogens via formation of estrogen quinones. 
Estrogen-3,4-quinones react with DNA to form mutagenic depurinating estrogen-DNA adducts. The carcinogenicity of 
endogenous estrogens is related to unbalanced estrogen metabolism leading to excess estrogen quinones and formation of 
depurinating DNA adducts. The present studies were initiated to conﬁ  rm that relatively high levels of depurinating estrogen-
DNA adducts are present in women at high risk for breast cancer or diagnosed with the disease. These adducts may be 
biomarkers for early detection of breast cancer risk. The estrogen metabolites, conjugates and depurinating DNA adducts 
were identiﬁ  ed and quantiﬁ  ed by using ultraperformance liquid chromatography/tandem mass spectrometry to analyze urine 
samples from 40 healthy control women, 40 high-risk women and 40 women with newly diagnosed breast cancer. Estrogen 
metabolism was shifted from protective methoxylation and conjugation pathways in healthy control women towards activating 
pathways leading to formation of depurinating DNA adducts in women at high risk or with breast cancer. These results 
support the hypothesis that breast cancer is initiated by mutations derived from depurination of estrogen-DNA adducts. 
Therefore, relative levels of depurinating estrogen-DNA adducts could become biomarkers for early detection of breast 
cancer risk and aid in determining preventive strategies.
Keywords: breast cancer risk, depurinating estrogen-DNA adducts, urinary estrogen biomarkers, balance in estrogen 
metabolism
Introduction
Estrogens, which contain a benzene ring, can become endogenous carcinogens. Three lines of evidence 
support this concept. Exposure to estrogens is a risk factor for increased incidence of breast cancer.
1,2 
Other evidence derives from the similar reaction of benzene ortho-quinone and estrogen ortho-quinones 
with nucleophiles. In fact, these two compounds react with DNA to form analogous depurinating DNA 
adducts.
3 Exposure to benzene is a risk factor for lymphoma and leukemia.
4,5 Finally, the ortho-
quinones of benzene and estradiol (E2) induce similar hyperproliferation of human peripheral blood 
mononuclear cells.
6
In an earlier study, we have shown that in healthy control women (n = 46) whose estrogen metabo-
lism is considered balanced, the level of estrogen-DNA adducts in urine is low and/or the levels of 
estrogen catechol metabolites, and thiol and methyl conjugates are high. In contrast, in high-risk women 
(n = 12) and those with breast cancer (n = 17), the unbalanced estrogen metabolism is reﬂ  ected in higher 
levels of estrogen-DNA adducts in urine and/or lower levels of estrogen metabolites and conjugates.
7 
It is this imbalance in estrogen metabolism, leading to relatively high levels of estrogen-DNA adducts, 
that is the determinant of breast cancer initiation (Fig. 1). In principle, environmental, genetic, as well 
as dietary, factors can unbalance the equilibrium between the activating and deactivating pathways of 
estrogen metabolism.
Once released from DNA, the predominant depurinating estrogen-DNA adducts, 4-hydroxyestrone 
(estradiol)-1-N3Adenine [4-OHE1(E2)-1-N3Ade] and 4-hydroxyestrone(estradiol)-1-N7Guanine 2
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[4-OHE1(E2)-1-N7Gua]
8–10 are shed from cells into 
the bloodstream and, eventually, excreted in urine.
7 
Release of the depurinating adducts generates 
apurinic sites in the DNA, which in turn induce 
mutations. It is thought that critical mutations 
generated by speciﬁ  c DNA damage can result in 
abnormal cell proliferation leading to cancer.
11–15 
The transforming activity of E2 and 4-OHE2 has 
been observed in human breast epithelial (MCF-
10 F) cells, which do not contain estrogen receptor-α, 
and are not affected by the presence of an 
anti-estrogen.
16–19 E6 mouse mammary cells were 
also transformed by treatment with E2-3,4-quinone 
(Q).
20 Furthermore, 4-OHE1(E2) are carcinogenic in 
the Syrian golden hamster and CD-1 mouse.
21–24 All 
of these studies support the hypothesis that estrogens 
initiate cancer through their genotoxicity.
In light of our earlier ﬁ  ndings,
7 we wanted to 
validate them with a larger number of participants. 
We conducted a cross-sectional study in which 
40 estrogen metabolites, conjugates and depurinating 
DNA adducts were analyzed in urine samples from 
40 healthy control women, 40 women at high risk for 
breast cancer based on a Gail Model score  1.66%, 
and 40 women with newly diagnosed Stage 0, 1 and 2 
breast carcinoma (in-situ and invasive carcinoma), 
all recruited at the Mayo Clinic. The results pre-
sented here provide further support that the ratios of 
depurinating DNA adducts to their respective estro-
gen metabolites and conjugates were signiﬁ  cantly 
associated with risk status.
Materials and Methods
Materials
Phenyl solid phase extraction (SPE) cartridges 
were purchased from Varian (Palo Alto, CA). 
Androstenedione 1, testosterone 2, E1-sulfate 3, 
E2 4, E1 5, 2-OHE2 6, 2-OHE1 7, 16α-OHE2 10, 
16α-OHE1 11, 2-OCH3E2 12, 2-OCH3E1 13, 
4-OCH3E2 14, 4-OCH3E1 15, 2-OH-3-OCH3E2 16 
Figure 1. Biosynthesis and metabolic activation of the estrogens E1 and E2. One of the major metabolic pathways of E1 and E2 leads to 
2- and 4-catechol derivatives, which further oxidize to yield the corresponding reactive quinones. The quinones can react with DNA to form 
depurinating DNA adducts. In the deactivation pathway, which operates in parallel, the catechol derivatives are methylated to form methoxy 
catechol estrogens; in addition, the quinones are reduced by quinone reductase, as well as being conjugated with GSH, and, are thus ren-
dered harmless. A shift in the apparent balance between these activating and deactivating pathways towards formation of depurinating DNA 
adducts could lead to the initiation of breast cancer.3
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and 2-OH-3-OCH3E1 17 were purchased from 
Steraloids, Inc. (Newport, RI). 4-OHE2 8 and 
4-OHE1 9 were synthesized as previously described.
25 
2-OHE2-1-glutathione (SG) 18, 2-OHE2-4-SG 19, 
2-OHE1-1-SG 20, 2-OHE1-4-SG 21, 2-OHE2-(1 + 4)-
cysteine (Cys) 22, 2-OHE1-1-Cys 23, 2-OHE1-4-
Cys 24, 2-OHE2-1-N-acetylcysteine (NAcCys) 25, 
2-OHE2-4-NAcCys 26, 2-OHE1-1-NAcCys 27, 
2-OHE1-4-NAcCys 28, 4-OHE2-2-SG 29, 4-OHE1-
2-SG 30, 4-OHE2-2-Cys 31, 4-OHE1-2-Cys 32, 
4-OHE2-2-NAcCys 33 and 4-OHE1-2-NAcCys 34 
were synthesized by using the procedure of Cao 
et al.
26 4-OHE2-1-N7Gua 35, 4-OHE1-1-N7Gua 
36, 4-OHE2-1-N3Ade 37, 4-OHE1-1-N3Ade 38, 
2-OHE2-6-N3Ade 39 and 2-OHE1-6-N3Ade 
40 were synthesized by following reported 
methods.
9,10,27 All solvents were HPLC grade and 
all other chemicals used were of the highest grade 
available.
Study population
Spot urine samples were collected from 120 women 
at the Breast Diagnostic Clinic and Oncology 
Breast Clinic of the Mayo Clinic, Rochester, 
Minnesota. Women were recruited between 
October 2006 and December 2007 and their ages 
ranged between 23 and 84 years. Healthy control 
women: range, 23–63; median, 44.5 years; high-
risk women: range, 35–76; median, 57.3 years; 
women with breast cancer: range, 35–84; median, 
57.8 years.
The 40 healthy control women had not received 
a diagnosis of breast cancer at the time of their urine 
collection and had a calculated Gail Model score 
of   1.66%. Among the 40 high-risk women, their 
Gail Model scores were 1.67%–11.7%. The Gail 
Model is a validated tool developed by the National 
Cancer Institute 
28 that takes into account a woman’s 
age, number of breast biopsies and prior history of 
atypical hyperplasia, age at menarche, and number 
of affected ﬁ  rst degree relatives. It calculates both 
a 5-year risk and lifetime risk. A 5-year Gail Model 
score of  1.66% is considered high risk. The ﬁ  nal 
40 participants were diagnosed with Stage 0, 1 and 2 
breast cancer within 30 days of providing the urine 
sample. None of the participants received estrogen-
containing treatment for at least 3 months prior to 
providing a urine sample.
The protocol was approved by the Mayo Clinic 
and UNMC Institutional Review Boards. Signed 
consents included authorization to collect and bank 
urine samples and collect demographic and clinical 
information.
Sample collection
A spot urine sample of about 50 ml was collected 
from each participant and 1 mg/ml ascorbic acid 
was added to prevent oxidation of the catechol 
moieties in the various estrogen compounds. The 
urine samples were aliquoted, frozen, and four 
10-ml aliquots were transferred to the Eppley 
Institute, UNMC, on dry ice and stored at −80 °C 
until analysis. Thus, each analytical sample was 
thawed only once prior to analysis.
Solid phase extraction of urine
The SPE method development and validation were 
described earlier.
7 Brieﬂ  y, after adjusting 2-ml 
aliquots of urine to pH 7, they were loaded onto 
the 100-mg phenyl cartridges pre-conditioned with 
methanol and the loading buffer, 10 mM ammonium 
formate, pH 7. The cartridges were washed with 
the loading buffer, and then the compounds of 
interest were eluted from the cartridge by using an 
elution buffer, methanol:10 mM ammonium for-
mate, pH 7 (90:10), with 1% acetic acid. The elu-
ates from both the experimental and control 
samples were concentrated and subjected to ultra-
performance liquid chromatography/tandem mass 
spectrometry (UPLC/MS-MS) analysis.
We previously found that the treatment of urine 
with glucuronidase/sulfatase led to signiﬁ  cant 
increases (10–20 fold) in the levels of E1 and E2, 
however, the levels of estrogen metabolites, 
conjugates and adducts changed marginally and in 
many cases decreased because of the incubation 
for 8 h at 37 °C. Hence, to avoid artifacts and errors 
that are introduced by maintaining the urine 
samples at 37 °C for 8 h, we carried out all the 
analyses without treating the samples with 
glucuronidase/sulfatase. For this reason, the 
reported levels of E1 and E2 are 10–15 times less 
than the total values.
7
UPLC/MS-MS analysis
of urine samples
All experiments were performed on a Waters 
(Milford, MA) Quattro Micro triple quadrupole 
mass spectrometer by using electrospray ionization 
(ESI) in positive ion (PI) and negative ion (NI) 
mode, with an ESI-MS capillary voltage of 3.0 kV, 4
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an extractor cone voltage of 2 V, and a detector 
voltage of 650 V. Desolvation and cone gas ﬂ  ow 
were maintained at 400 and 60 l/h respectively. 
Desolvation temperature and source temperature 
were set to 200 and 100 °C, respectively. For all 
the studies, a methanol:water (1:1) mixture with 
0.1% formic acid was used as the carrier solution. 
The parent and daughter ion data obtained for all 
standard compounds were used to generate the 
multiple reaction monitoring (MRM) method for 
UPLC/MS-MS operation.
7
UPLC/MS analyses of estrogen-related 
compounds (Table 1) in urine extracts were carried 
out with a Waters Acquity UPLC system con-
nected with the high performance Quattro Micro 
triple quadrupole mass spectrometer. Analytical 
separations on the UPLC system were conducted 
using an Acquity UPLC BEH C18 1.7 μm column 
(1 × 100 mm) at a ﬂ  ow rate of 0.15 ml/min. The 
gradient started with 80% A (0.1% formic acid in 
H2O) and 20% B (0.1% formic acid in acetonitrile), 
changed to 79% A over 4 min, followed by a 6-min 
linear gradient to 45% A, resulting in a total separa-
tion time of 10 min. The levels of compounds were 
normalized to the concentration of creatinine (Cr). 
The elutions from the UPLC column were intro-
duced to the Quattro Micro mass spectrometer. 
Resulting data were processed by using QuanLynx 
software (Waters) to quantify the estrogen 
metabolites, conjugates and DNA adducts.
7
Statistical Analyses
Statistical methods
Median values were calculated for all estrogen 
compounds obtained from healthy control, high 
risk and breast cancer groups. Ratios were 
compared for healthy control vs. high risk and for 
healthy control vs. breast cancer using one-way 
ANOVA. Additional post hoc analysis was done 
for multiple comparisons using Dunn’s method. 
All the statistics and p-values were calculated using 
GraphPad Prism software V 4.03 (GraphPad 
Software, La Jolla, CA).
Results and Discussion
Using the SPE/UPLC/MS-MS methodology 
recently developed by our laboratory,
7 we have 
analyzed urine samples from various groups of 
women for 40 estrogen-related compounds (Fig. 1). 
This analysis resulted in data reporting the 
concentration of each of the 40 compounds (Table 1). 
Furthermore, we calculated the ratio of depurinating 
N3Ade and N7Gua adducts to the sum of their 
respective estrogen metabolites and conjugates in 
the urine samples because this ratio reﬂ  ects the 
degree of imbalance in estrogen metabolism that can 
lead to cancer initiation (Fig. 1).
The ratios in healthy control women are 
generally low (Fig. 2). In contrast, high ratios of 
these adducts to estrogen metabolites and conjugates 
were observed in urine from high-risk women (Gail 
Model score  1.66%) and women with breast 
carcinoma (Fig. 2). In general, the value obtained 
from the high-risk women and women with breast 
carcinoma derives from the ratio between a high 
level of adducts and low levels of metabolites and 
conjugates. In some women, however, the level of 
adducts was not particularly high, but the levels of 
metabolites and conjugates were very low, suggest-
ing that a substantial proportion of the metabolites 
was converted to adducts. In addition, the average 
contribution of the 2-OHE1(E2)-6-N3Ade adducts 
to the total ratio was found to be insigniﬁ  cant, 
whereas the predominant contribution was from 
the 4-OHE1(E2)-1-N3Ade and 4-OHE1(E2)-1-N7Gua 
adducts.
7 The healthy control women had a lower 
median age than the high-risk and breast cancer 
women. Multiple linear regression comparison of 
the ratios between the three groups after adjusting 
for age indicated that the median ratio for the 
healthy control women group is still signiﬁ  cantly 
different from the median ratios for the high-risk 
and breast cancer groups. The median ratios for the 
high-risk and breast cancer groups are not signiﬁ  -
cantly different. The results obtained in this study 
are similar to those obtained by analyzing serum 
samples collected from the same women.
29
As seen in our earlier study, analysis of the ratio 
using one-way ANOVA reveals a signiﬁ  cant dif-
ference between the high-risk and breast cancer 
groups compared to the healthy control group 
(p   0.001) (Fig. 3). Additional post hoc analysis 
using a Dunn’s correction for multiple comparisons 
revealed signiﬁ  cantly higher means for high-risk 
subjects [mean 232, standard deviation (SD) 340] 
compared with healthy controls (mean 34.7, SD 
31.6, p   0.001) and for breast cancer patients 
(mean 188, SD 235, p   0.001) compared to con-
trols (Fig. 3). The mean for subjects known to be 
at high risk was not signiﬁ  cantly different from 
that of the breast cancer group (Fig. 3).5
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Table 1. Representative metabolic proﬁ  le of a urine sample obtained from a high-risk woman.
No. Compound pmol/mg Cr
mean, n = 3
Total
pmol/mg Cr
1 Androstenedione 0.7 ± 0.1
a 0.7
2 Testosterone 0.0 ± 0.0 0.0
3E 1-Sulfate 3.3 ± 0.8 3.3
4E 2 0.6 ± 0.3
5.4
5E 1 4.8 ± 0.8
6 2-OHE2 1.6 ± 1.5
1.6
7 2-OHE1 0.0 ± 0.0
8 4-OHE2 0.0 ± 0.0
0.0
9 4-OHE1 0.0 ± 0.0
10 16α-OHE2 6.4 ± 3.2
93.9
11 16α-OHE1 87.5 ± 25.9
12 2-OCH3E2 4.5 ± 0.8
35.5
13 2-OCH3E1 31.0 ± 10.5
14 4-OCH3E2 2.0 ± 0.8
8.3
15 4-OCH3E1 6.3 ± 4.5
16 2-OH-3-OCH3E2 0.0 ± 0.0
0.0
17 2-OH-3-OCH3E1 0.0 ± 0.0
18 2-OHE2-1-SG 0.0 ± 0.0
1.4
19 2-OCH2-4-SG 0.0 ± 0.0
20 2-OHE1-1-SG 0.5 ± 0.3
21 2-OHE1-4-SG 0.5 ± 0.3
22 2-OHE2-1+4-Cys 0.2 ± 0.2
23 2-OHE1-1-Cys 0.0 ± 0.0
24 2-OHE1-4-Cys 0.0 ± 0.0
25 2-OHE2-1-NAcCys 0.0 ± 0.1
26 2-OHE2-4-NAcCys 0.0 ± 0.1
27 2-OHE1-1-NAcCys 0.0 ± 0.0
28 2-OHE1-4-NAcCys 0.0 ± 0.0
29 4-OHE2-2-SG 0.3 ± 0.2
0.8
30 4-OHE1-2-SG 0.4 ± 0.3
31 4-OHE2-2-Cys 0.0 ± 0.0
32 4-OHE1-2-Cys 0.0 ± 0.0
33 4-OHE2-2-NAcCys 0.0 ± 0.0
34 4-OHE1-2-NAcCys 0.0 ± 0.0
35 4-OHE2-1-N7Gua 0.01 ± 0.01
4.63
36 4-OHE1-1-N7Gua 4.62 ± 2.39
37 4-OHE2-1-N3Ade 0.96 ± 0.08
1.02
38 4-OHE1-1-N3Ade 0.06 ± 0.04
39 2-OHE2-6-N3Ade 0.03 ± 0.03
0.03 40 2-OHE1-6-N3Ade 0.0 ± 0.0
aMean ± standard deviation.6
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Each sample was analyzed in triplicate and the 
mean values were calculated for all 40 compounds 
(Table 1). Finally, the median values obtained for 
selected compounds using the 40 samples in the 
three different groups were graphed (Fig. 4). As 
seen in our earlier study, the median 4-OHE1(E2), 
4-OCH3E1(E2) and 4-OHE1(E2)-thiol conjugate 
(GSH, Cys, NAcCys) values were higher for 
healthy controls compared with high-risk subjects 
and breast cancer cases (Fig. 4A). In contrast, the 
median 4-OHE1(E2)-1-N3Ade and 4-OHE1(E2)-
1-N7Gua values were lower for healthy controls 
compared with high-risk subjects and breast cancer 
cases (Fig. 4A). Compared with breast cancer cases 
and high-risk subjects, the median 2-OHE1(E2), 
2-OCH3E1(E2), and 2-OHE1(E2)-thiol conjugate 
values were higher for healthy controls (Fig. 4B), 
while the median 2-OHE1(E2)-6-N3Ade values did 
not show any trend. The rest of the metabolites 
(Table 1) are not shown because they are not 
included in the calculation of the ratios or they did 
not show any signiﬁ  cant trend in the three groups.
In conclusion, these results conﬁ  rm our previous 
ﬁ  nding of high ratios of depurinating estrogen-DNA 
adducts to their corresponding metabolites and 
conjugates in urine samples from both high-risk 
women and women with breast cancer, compared 
to lower ratios in healthy control women.
7 This 
ﬁ  nding is consistent with the hypothesis that for-
mation of estrogen-DNA adducts is the ﬁ  rst critical 
step in the initiation of breast cancer. These results 
suggest that a urine assay may provide a screening 
biomarker for early detection of breast cancer risk. 
However, further larger studies are required to 
know how far in advance this assay would predict 
the development of a clinically or mammographi-
cally detectable tumor.
Conclusion
The ratio of depurinating estrogen-DNA adducts 
to their metabolites and conjugates may be a urine 
biomarker to quantify an individual’s risk and 
determine appropriate risk reducing strategies. 
Another use of the urine assay could be to assess 
the ability of natural antioxidants to balance 
estrogen activation and deactivation, thereby 
reducing the risk of developing breast cancer.
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Figure 4. A) Urinary median levels of 4-OHE1(E2), 4-OCH3E1(E2) and 4-OHE1(E2)-thiol conjugates, as well as 4-OHE1(E2)-1-N3Ade and 
4-OHE1(E2)-1-N7Gua adducts in urine samples from 40 healthy control women, 40 high-risk women and 40 women with breast cancer. 
B) Urinary median levels of 2-OHE1(E2), 2-OCH3E1(E2) and 2-OHE1(E2)-thiol conjugates, as well as the 2-OHE1(E2)-6-N3Ade adducts, in 
urine samples from 40 healthy control women, 40 high-risk women and 40 women with breast cancer.8
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